BURLINGTON, Mass., Nov. 1, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the generic erosion of key high-priced brands, the acute coronary syndrome drug market will decline from approximately $923 million in 2009 to $809 million in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Thereafter, the market will rise to $815 million by 2019 due to the launches and uptake of novel antithrombotic therapies.
The Pharmacor 2010 findings from the topic entitled Acute Coronary Syndrome reveal that the market for post-hospital, prevalent cases of the indication will initially contract from $1.3 billion in 2009 to about $1.2 billion in 2012, due mainly to the generic availability of clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis's Plavix/Iscover, generics). The market for post-hospital acute coronary syndrome will then increase to just over $1.9 billion in 2019 owing to uptake of novel antithrombotics such as AstraZeneca's Brilinta/Brilique (ticagrelor). Additionally, in the acute setting, generic erosion of Merck/GlaxoSmithKline's Integrilin -- a glycoprotein IIb/IIIa inhibitor -- and the general reduction in the use of this drug class will cause a decline of more than $200 million though 2019.
The Pharmacor 2010 findings reveal that the most advanced agent in development, ticagrelor, is also the drug most likely to change medical practice in acute coronary syndrome.
"In a Phase III clinical trial, ticagrelor significantly reduced the risk of mortality compared with clopidogrel, which has been a mainstay of acute coronary syndrome therapy," said Decision Resources Analyst Conor Walsh, Ph.D. "After its initial launch in 2011, we forecast major-market sales of more than $7 million in 2019 for ticagrelor in the acute treatment setting and more than $300 million in the post-hospital setting."
In the acute setting, higher-priced anticoagulants such as The Medicines Company's Angiomax/Angiox and Sanofi-Aventis's Lovenox/Clexane and otamixaban are expected to gradually capture share at the expense of unfractionated heparin in patients treated with percutaneous coronary intervention. This trend will partly offset the sales decline in this class due to the generic erosion of Lovenox/Clexane and Angiomax/Angiox through 2019.
About Pharmacor 2010
The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
SOURCE Decision Resources